Vivos Inc. Expands IsoPet Therapy to Exotic Animals Offering Hope
Vivos Inc. Expands IsoPet Therapy to Exotic Animals
Vivos Inc. (OTCQB: RDGL) is making significant strides in its innovative approach to cancer treatment with the introduction of IsoPet® Precision Radionuclide TherapyTM for exotic animals. Recently, this pioneering company treated a ferret, achieving promising results that included a notable reduction in tumor size within three weeks. Adult exotic animals often have limited treatment options, and traditional methods like surgical removal can be overly invasive.
Dr. Korenko Highlights Growing Demand
Dr. Michael K. Korenko, President and CEO of Vivos Inc., emphasized the increasing need for effective cancer treatments tailored to a broader range of animals, not just common pets. "While we have experience treating cats, dogs, and horses, the demand for solutions aimed at exotic pets and zoo animals is becoming more pressing. Engaging in conferences helps us raise awareness about IsoPet Therapy as a viable option for treating cancerous tumors," he stated.
What is IsoPet Therapy?
IsoPet® utilizes a state-of-the-art Yttrium-90-based injectable therapy to combat tumors in both animals and humans. By employing proprietary hydrogel technology, this therapy delivers radiation directly to the tumor site. It is designed to manage cancers that are non-resectable or resistant to other forms of radiation, making it a unique solution in the veterinary oncology landscape.
How IsoPet Slashes Treatment Times
One of the remarkable aspects of IsoPet® is its efficient delivery system. Since its short-range beta radiation targets only the tumor area, it minimizes damage to surrounding tissues. In fact, more than 90% of the therapeutic radiation is released within just ten days. This efficiency means that patients can undergo treatment as outpatients, ultimately returning home without elevated radiation concerns for their families.
Past Research and Future Directions
Research conducted at respected university veterinary hospitals confirms the safety and effectiveness of IsoPet® for various cancers. For instance, significant studies concerning feline sarcomas have been completed successfully, paving the way for further use. Following a thorough FDA review, IsoPet® was classified as a medical device, simplifying the pathway for veterinarians to utilize this therapy in practices nationwide and ensuring that animals receive the best possible care.
Synergy between IsoPet and RadioGel®
IsoPet® operates under the same technological principles as RadioGel®, which is applied in human cancer treatments. Although both products use potent Yttrium-90, they are differentiated by unique branding to prevent any mix-up between veterinary and human applications. This strategic decision underscores Vivos Inc.'s commitment to clarity and safety in its therapeutic offerings.
Looking Ahead
As Vivos Inc. forges ahead, it remains focused on expanding its services and enhancing patient care. The shift towards treating exotic animals marks a substantial evolution in their business model, aligning with both the company's mission and the needs of pet owners seeking alternative cancer treatments for their beloved companions.
For inquiries, Michael K. Korenko can be contacted via email at MKorenko@RadioGel.com. Stay updated by following Vivos Inc on X (Twitter) at @VivosIncUSA and the companies Radiogel and IsoPet.
Frequently Asked Questions
What is IsoPet® therapy?
IsoPet® therapy is a precision radionuclide treatment developed by Vivos Inc. to target cancerous tumors in both pets and exotic animals using Yttrium-90.
How does IsoPet® work?
This therapy delivers radiation directly to the tumor via hydrogel technology, leading to effective tumor control while sparing surrounding healthy tissue.
What animals can be treated with IsoPet®?
Initially tailored for common pets like cats and dogs, IsoPet® has expanded to include exotic animals, showcasing its versatility in veterinary applications.
Is IsoPet® safe for pets?
Yes, IsoPet® has been validated through rigorous research, confirming its safety and efficacy in treating various types of tumors in animals.
Who can I contact for more information?
You can reach out to Michael K. Korenko, the CEO of Vivos Inc., via email at MKorenko@RadioGel.com for further inquiries.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
